• Home
  •  / Seneca Biopharma

Seneca Biopharma

OverviewSuggest Edit

Seneca Biopharma (formerly NeuralStem) is a clinical-stage biopharmaceutical company. The Company's patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the potential treatment of Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS and Parkinsona's Disease. NeuralStem's research has allowed them to produce mature, commercial quantities of neural stem cells that can be transplanted into humans as treatments for currently incurable diseases.

TypePublic
Founded1996
HQGermantown, USMap
Websitesenecabio.com

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2019)5(-54%)
Revenue (FY, 2019)$15.4 K(-94%)
Share Price (Nov 2019)$1.2 (+7%)
Cybersecurity ratingAMore

Key People/Management at Seneca Biopharma

Kenneth C. Carter

Kenneth C. Carter

Executive Chairman
Cristina Csimma

Cristina Csimma

Director
Matthew Kalnik

Matthew Kalnik

President & Chief Operating Officer
David Recker

David Recker

Chief Medical Officer
Mary Ann Gray

Mary Ann Gray

Director
Thomas Hazel

Thomas Hazel

Senior Vice President, Research
Show more

Seneca Biopharma Office Locations

Seneca Biopharma has offices in Germantown and Rockville
Germantown, US (HQ)
Goldrenrod Building, 20271 Goldenrod Ln #2024
Rockville, US
9700 Great Seneca Hwy
Show all (2)

Seneca Biopharma Financials and Metrics

Seneca Biopharma Revenue

Seneca Biopharma's revenue was reported to be $15.39 k in FY, 2019
USD

Revenue (Q2, 2020)

2.5k

Net income (Q2, 2020)

(2.0m)

EBIT (Q2, 2020)

(1.9m)

Market capitalization (31-Oct-2019)

4.0m

Closing stock price (31-Oct-2019)

1.5

Cash (30-Jun-2020)

15.8m

EV

(11.7m)
Seneca Biopharma's current market capitalization is $4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

390.6k407.7k110.0k18.8k10.4k16.2k260.0k260.0k15.4k

General and administrative expense

5.8m256.0k5.3m9.0m6.5m7.5m5.5m4.6m4.6m

R&D expense

7.4m6.1m7.1m8.1m12.6m13.2m8.1m4.0m4.1m

Operating expense total

13.2m6.4m12.4m17.1m19.2m20.7m13.6m8.5m8.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

103.4k156.3k78.1k170.8k102.5k2.5k2.5k4.2k5.0k5.0k2.9k2.5k2.5k2.5k2.5k2.5k2.5k2.5k2.5k2.5k252.5k2.5k2.5k7.9k2.5k6.0k2.5k

General and administrative expense

1.5m1.1m1.2m821.4k1.3m1.2m1.3m1.7m3.5m1.5m2.0m1.4m1.7m1.8m3.2m1.4m1.3m1.3m1.6m1.2m1.2m1.3m1.2m944.6k971.8k1.3m1.3m1.5m

R&D expense

2.1m2.1m1.4m1.6m1.4m1.7m1.9m1.8m1.6m1.9m2.1m3.2m3.3m3.4m3.1m2.5m3.6m2.9m2.6m1.4m1.2m1.0m897.1k1.5m954.5k825.5k696.9k446.0k

Operating expense total

3.6m3.3m2.6m2.4m2.7m2.9m3.2m3.6m5.1m3.4m4.0m4.6m5.0m5.2m6.2m3.8m4.9m4.2m4.2m2.6m2.4m2.3m2.1m2.5m1.9m2.1m2.0m1.9m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

2.4m7.4m16.8m12.5m4.7m15.2m6.7m5.8m5.1m

Accounts Receivable

234.4k3.3k10.0k225.5k37.3k312.8k294.1k21.1k

Prepaid Expenses

430.4k205.7k255.7k274.1k1.2m402.3k363.3k510.9k

Inventories

Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

6.1m4.2m5.1m2.5m9.9m12.7m11.2m16.4m18.3m15.2m11.9m13.6m8.6m13.1m7.6m11.1m5.7m11.7m6.4m9.1m9.7m7.1m5.7m4.0m2.3m7.3m10.0m15.8m

Accounts Receivable

234.4k56.9k833.0104.3k56.8k7.5k11.4k24.5k32.8k8.2k18.8k19.2k39.2k5.1k12.7k14.7k5.3k37.5k137.4k478.7k162.0k237.8k169.9k61.2k19.0k16.9k

Prepaid Expenses

300.7k653.9k404.6k234.2k289.8k220.9k156.6k344.0k319.6k196.2k409.1k388.1k904.2k1.3m1.1m705.8k946.9k477.1k239.3k548.8k347.0k343.4k545.2k295.4k256.8k605.3k414.7k390.6k

Current Assets

6.4m4.8m5.8m2.8m10.2m13.5m12.0m17.3m34.1m30.8m27.7m29.2m24.7m19.6m8.7m11.8m6.7m17.2m11.7m14.7m10.2m7.9m6.5m4.5m2.7m8.0m10.5m16.2m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(12.5m)(10.1m)(19.8m)(22.6m)(20.9m)(21.1m)(15.7m)(4.9m)(8.4m)

Depreciation and Amortization

187.1k211.1k244.7k348.6k345.5k337.5k289.2k185.8k143.9k

Accounts Payable

888.3k(644.0k)(116.7k)1.4m(1.0m)879.1k(1.5m)(37.0k)(15.7k)

Cash From Operating Activities

(8.1m)(8.5m)(10.6m)(11.7m)(18.9m)(15.6m)(13.4m)(7.7m)(7.3m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(6.8m)(10.0m)(2.5m)(4.8m)(7.4m)(3.6m)(9.8m)(16.5m)(5.9m)(12.7m)(17.1m)(5.1m)(10.5m)(16.1m)(6.6m)(10.5m)(15.7m)(7.6m)(12.2m)(12.4m)(2.1m)(2.8m)(4.6m)(3.1m)(4.6m)(6.3m)(7.6m)(9.5m)

Depreciation and Amortization

85.3k149.5k34.9k76.2k164.2k50.1k100.6k182.0k90.5k177.2k260.2k83.8k167.4k255.4k85.5k177.5k275.1k112.2k180.6k233.6k67.4k114.3k160.5k39.8k77.2k113.7k29.1k57.7k

Accounts Payable

(182.4k)438.6k(189.1k)(694.5k)(342.3k)44.1k(430.3k)(97.1k)184.7k465.6k899.3k(376.0k)(405.1k)(1.3m)1.2m955.2k1.0m(227.6k)(160.7k)(920.6k)293.1k(151.7k)(25.5k)244.3k208.5k340.7k138.6k(279.9k)

Cash From Operating Activities

(4.5m)(6.3m)(2.1m)(4.5m)(6.0m)(2.5m)(5.9m)(8.1m)(2.7m)(5.1m)(8.2m)(4.7m)(9.5m)(15.0m)(3.5m)(7.1m)(11.5m)(4.4m)(7.8m)(11.1m)(1.8m)(4.4m)(6.0m)(1.7m)(3.3m)(5.2m)(1.7m)(3.7m)
show all
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

Seneca Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

Learn more about our premium products
SecurityScorecard logo

Seneca Biopharma Online and Social Media Presence

Seneca Biopharma's Trends

Embed Graph

Seneca Biopharma News and Updates

May 22, 2020

Seneca Biopharma Announces Pricing of $5 Million Registered Direct Offering Priced At-the-Market

GERMANTOWN, Md., May 22, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet medical need, today announced that it has entered into definitive agreements with several...
April 01, 2020

Seneca Biopharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GERMANTOWN, Md., April 1, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need, announced today, that the Compensation Committee of the Board of Directors of Seneca...
March 27, 2020

Seneca Biopharma, Inc. Reports Year End 2019 Fiscal Results

GERMANTOWN, Md., March 27, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today reported its financial results for the year ended December 31, 2019. Business Highlights...
October 03, 2019

Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4)

GERMANTOWN, Md., Oct. 3, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, announced the adjustment of an options award that was previously...
September 24, 2019

Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

GERMANTOWN, Md., Sept. 24, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced completion of subject enrollment in its Phase 2 clinical trial of NSI-566 for the treatment of chronic...
August 14, 2019

Neuralstem Reports Second Quarter 2019 Fiscal Results

GERMANTOWN, Md., Aug. 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, reported its financial results for the second quarter ended June...
Show more

 Seneca Biopharma Frequently Asked Questions

  • When was Seneca Biopharma founded?

    Seneca Biopharma was founded in 1996.

  • Who are Seneca Biopharma key executives?

    Seneca Biopharma's key executives are Kenneth C. Carter, Cristina Csimma and Matthew Kalnik.

  • How many employees does Seneca Biopharma have?

    Seneca Biopharma has 5 employees.

  • What is Seneca Biopharma revenue?

    Latest Seneca Biopharma annual revenue is $15.4 k.

  • What is Seneca Biopharma revenue per employee?

    Latest Seneca Biopharma revenue per employee is $3.1 k.

  • Who are Seneca Biopharma competitors?

    Competitors of Seneca Biopharma include InVivo Therapeutics, MedDay and Bicycle Therapeutics.

  • Where is Seneca Biopharma headquarters?

    Seneca Biopharma headquarters is located at Goldrenrod Building, 20271 Goldenrod Ln #2024, Germantown.

  • Where are Seneca Biopharma offices?

    Seneca Biopharma has offices in Germantown and Rockville.

  • How many offices does Seneca Biopharma have?

    Seneca Biopharma has 2 offices.